• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Abstract 143: Pregnancy Dependant Transcriptomic Changes in Uterine Arteries From Hypertensive and Normotensive Rat Models Session Title: Developmental Programming and Pregnancy Induced Hypertension
This study investigated early gene expression changes in the uterine arteries (UA) of pregnant SHRSP and normotensive Wistar Kyoto (WKY) rats.Methods: SHRSP and WKY females were time mated and UA isolated at gestational day (GD)6 (n=3). Non-pregnant (NP) UA were isolated from virgin aged matched controls (n=3). UA RNAseq (Illumina platform) was performed. Transcript level gene changes were interpreted using Ingenuity Pathway Analysis (FDR 1.0). Quantitative RT-PCR was used to validate significantly differentially expressed genes.Results: There was a greater number of differentially expressed transcripts NP v GD6 in SHRSP c...
Source: Hypertension - September 14, 2017 Category: Cardiology Authors: Hannah L Morgan, Elisabeth Beattie, Martin W McBride, Delyth Graham Tags: Oral Abstract Presentations Source Type: research

Postpartum Increases in Cerebral Edema and Inflammation in response to Placental Ischemia during Pregnancy
Publication date: Available online 26 March 2018 Source:Brain, Behavior, and Immunity Author(s): Ahsia M. Clayton, Qingmei Shao, Nina D. Paauw, Ashtin B. Giambrone, Joey P. Granger, Junie P. Warrington Reduced placental blood flow results in placental ischemia, an initiating event in the pathophysiology of preeclampsia, a hypertensive pregnancy disorder. While studies show increased mortality risk from Alzheimer’s disease, stroke, and cerebrovascular complications in women with a history of preeclampsia, the underlying mechanisms are unknown. During pregnancy, placental ischemia, induced by reducing uterine perfusion pr...
Source: Brain, Behavior, and Immunity - March 26, 2018 Category: Neurology Source Type: research

Postpartum Increases in Cerebral Edema and Inflammation in response to Placental Ischemia during Pregnancy.
Abstract Reduced placental blood flow results in placental ischemia, an initiating event in the pathophysiology of preeclampsia, a hypertensive pregnancy disorder. While studies show increased mortality risk from Alzheimer's disease, stroke, and cerebrovascular complications in women with a history of preeclampsia, the underlying mechanisms are unknown. During pregnancy, placental ischemia, induced by reducing uterine perfusion pressure (RUPP), leads to cerebral edema and increased blood-brain barrier (BBB) permeability; however whether these complications persist after delivery is not known. Therefore, we tested ...
Source: Brain, Behavior, and Immunity - March 24, 2018 Category: Neurology Authors: Clayton AM, Shao Q, Paauw ND, Giambrone AB, Granger JP, Warrington JP Tags: Brain Behav Immun Source Type: research

Impaired function of cerebral parenchymal arterioles in experimental preeclampsia
Publication date: Available online 26 April 2018 Source:Microvascular Research Author(s): Abbie C. Johnson, Marilyn J. Cipolla Preeclampsia (PE), a dangerous hypertensive complication of pregnancy, is associated with widespread maternal vascular dysfunction. However, the effect of PE on the cerebral vasculature that can lead to stroke and cognitive decline is not well understood. We hypothesized that function of cortical parenchymal arterioles (PAs) would be impaired during PE. Using a high cholesterol diet to induce experimental PE in rats (ePE), we studied the function and structure of isolated and pressurized PAs suppl...
Source: Microvascular Research - April 26, 2018 Category: Biochemistry Source Type: research

ACOG Committee Opinion No. 767: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period.
Authors: Abstract Acute-onset, severe systolic hypertension; severe diastolic hypertension; or both can occur during the prenatal, intrapartum, or postpartum periods. Pregnant women or women in the postpartum period with acute-onset, severe systolic hypertension; severe diastolic hypertension; or both require urgent antihypertensive therapy. Introducing standardized, evidence-based clinical guidelines for the management of patients with preeclampsia and eclampsia has been demonstrated to reduce the incidence of adverse maternal outcomes. Individuals and institutions should have mechanisms in place to initiate the...
Source: Obstetrics and Gynecology - December 19, 2018 Category: OBGYN Tags: Obstet Gynecol Source Type: research

ACOG Committee Opinion No. 767 Summary: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period.
Authors: Abstract Acute-onset, severe systolic hypertension; severe diastolic hypertension; or both can occur during the prenatal, intrapartum, or postpartum periods. Pregnant women or women in the postpartum period with acute-onset, severe systolic hypertension; severe diastolic hypertension; or both require urgent antihypertensive therapy. Introducing standardized, evidence-based clinical guidelines for the management of patients with preeclampsia and eclampsia has been demonstrated to reduce the incidence of adverse maternal outcomes. Individuals and institutions should have mechanisms in place to initiate the...
Source: Obstetrics and Gynecology - January 27, 2019 Category: OBGYN Tags: Obstet Gynecol Source Type: research

Current Treatment Options in Cardiovascular Medicine: Update on Reversible Cerebral Vasoconstriction Syndrome
ConclusionRCVS can now be accurately diagnosed using clinical and imaging features available upon presentation. Advances in knowledge about the risk factors, prognosis, and potential harmful effects of certain therapeutic strategies, are expected to optimize the management of this increasingly well recognized syndrome.
Source: Current Treatment Options in Cardiovascular Medicine - July 13, 2020 Category: Cardiology Source Type: research

No effect of calcium and vitamin D intake on maternal blood pressure in a healthy pregnant population
Pregnancy causes physiological changes in blood pressure (BP). In patients without pre-existing hypertension, BP falls during the first half of pregnancy and rises from 34 weeks onwards [1]. Hypertensive disorders in pregnancy (HDP) complicate approximately 10% of pregnancies and are associated with adverse outcomes for both mother and foetus [2]. Women with a history of HDP are also at increased risk of developing hypertension in later life as well as ischaemic heart disease, stroke and renal disease [3].
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - July 6, 2021 Category: OBGYN Authors: Hannah Forde, Rachel K. Crowley, Malachi J. McKenna, Mark T. Kilbane, Marie Conway, Ciara M. McDonnell, Patrick J. Twomey, Fionnuala M. McAuliffe Tags: Full length article Source Type: research

Polyuria, Polydipsia and Possible Diabetes Insipidus?
Discussion The body is smart. It has mechanisms for maintaining balances within the body in a closely controlled manner but allows for a variety of states. This is very true for fluid balance in the body which is highly controlled between almost all of the major body organ systems. When fluid is low, the sensor sends signals for us to drink, and conserves fluid until we can. When the fluid is high, the kidneys excrete the excess and sends signals not to drink. Usually it works very well. While there are many pathological states that can cause polyuria and/or polydipsia, the most common reason is excessive fluid intake beca...
Source: PediatricEducation.org - March 7, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

What the Science Says About the Health Benefits of Vitamins and Supplements
From multivitamins and melatonin to fiber and fish oil, Americans who are trying to boost their health and immunity have a plethora of supplements to choose from. An estimated 58% of U.S. adults ages 20 and over take dietary supplements, according to the U.S. Centers for Disease Control and Prevention, and the supplement industry is valued at more than $30 billion a year. Supplement use has been growing rapidly over the past few decades along with the wellness industry. “The popular belief is that a supplement is going to be helpful for promoting health,” says Fang Fang Zhang, a professor at Tufts University&rs...
Source: TIME: Health - April 28, 2022 Category: Consumer Health News Authors: Sandeep Ravindran Tags: Uncategorized Diet & Nutrition healthscienceclimate Source Type: news

U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news